Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Adaptive Biotechnologies, a commercial-stage biotechnology company focused on the adaptive immune system, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. The event will take place in Miami, FL, with a fireside chat scheduled for June 11, 2024, at 10:20 a.m. PT / 1:20 p.m. ET. The webcast of the presentation can be accessed live and archived on the company's website.
- Participation in a high-profile event like the Goldman Sachs Annual Global Healthcare Conference can enhance Adaptive Biotechnologies' visibility among investors and industry experts.
- The scheduled fireside chat offers a platform for the company to showcase its advancements and strategies to a targeted audience.
- The press release lacks specific financial data or clinical updates, which may not satisfy shareholders looking for concrete performance metrics.
- Absence of new product announcements or significant business developments could be seen as a lack of progress.
SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL.
Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, June 11th at 10:20 a.m. Pacific Time / 1:20 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com
FAQ
When is Adaptive Biotechnologies participating in the Goldman Sachs 45th Annual Global Healthcare Conference?
What time is Adaptive Biotechnologies' fireside chat at the Goldman Sachs conference?
Where can I access the webcast of Adaptive Biotechnologies' presentation at the Goldman Sachs conference?
What is the stock symbol for Adaptive Biotechnologies?
